Search Result

Results for "

inhibits cholesterol biosynthesis

" in MedChemExpress (MCE) Product Catalog:

標的別:	Apoptosis (4) Autophagy (5) Bacterial (1) c-Fms (1) c-Myc (1) Caspase (2) Cytochrome P450 (3) Deubiquitinase (1) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (1) Emopamil Binding Protein (1) Endogenous Metabolite (19) Farnesyl Transferase (4) Fatty Acid Synthase (FASN) (3) Ferroptosis (3) Fungal (1) Glutathione Peroxidase (2) Glycosyltransferase (1) GSK-3 (1) HIV (1) HMG-CoA Reductase (HMGCR) (5) Interleukin Related (2) Isotope-Labeled Compounds (2) JNK (3) LXR (6) NO Synthase (1) NOD-like Receptor (NLR) (2) Progesterone Receptor (1) Reactive Oxygen Species (ROS) (6) Reference Standards (4) γ-secretase (2)
研究分野別:	Cancer (10) Cardiovascular Disease (8) Infection (4) Inflammation/Immunology (4) Metabolic Disease (27) Neurological Disease (2)

標的別:

Apoptosis (4)

Autophagy (5)

Bacterial (1)

c-Fms (1)

c-Myc (1)

Caspase (2)

Cytochrome P450 (3)

Deubiquitinase (1)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (1)

Emopamil Binding Protein (1)

Endogenous Metabolite (19)

Farnesyl Transferase (4)

Fatty Acid Synthase (FASN) (3)

Ferroptosis (3)

Fungal (1)

Glutathione Peroxidase (2)

Glycosyltransferase (1)

GSK-3 (1)

HIV (1)

HMG-CoA Reductase (HMGCR) (5)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

JNK (3)

LXR (6)

NO Synthase (1)

NOD-like Receptor (NLR) (2)

Progesterone Receptor (1)

Reactive Oxygen Species (ROS) (6)

Reference Standards (4)

γ-secretase (2)

研究分野別:

Cancer (10)

Cardiovascular Disease (8)

Infection (4)

Inflammation/Immunology (4)

Metabolic Disease (27)

Neurological Disease (2)

阻害剤およびアゴニスト

天然物

同位体標識化合物

Targets Recommended: Acyltransferase

製品番号	製品名	Target	研究分野	構造式

HY-107420

AY 9944 Maximum Cited Publications 9 Publications Verification	Endogenous Metabolite	Metabolic Disease
AY 9944 is a specific **cholesterol biosynthesis** inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC₅₀ of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol .

HY-16274

Lapaquistat acetate 1 Publications Verification TAK-475	Farnesyl Transferase	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

HY-113224

Desmosterol 5 Publications Verification	Endogenous Metabolite LXR Fatty Acid Synthase (FASN) Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism . Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases .

HY-164561

TASIN-30 1 Publications Verification	Emopamil Binding Protein Ferroptosis Apoptosis	Cancer
TASIN-30 is a selective EBP inhibitor with an EC₅₀ of 0.097 μM. TASIN-30 blocks the production of 7-dehydrocholesterol (7-DHC) and downstream cholesterol biosynthesis processes. TASIN-30 depletes downstream sterols, disrupts the integrity of lipid rafts in tumor cells, accelerates intracellular cholesterol consumption, and inhibits tumor cell proliferation. TASIN-30 induces ferroptosis and apoptosis by reducing 7-DHC levels and increasing phospholipid peroxidation. TASIN-30 achieves tumor suppression in nude mice with osteosarcoma. TASIN-30 can be used in cancer-related research such as colorectal cancer and osteosarcoma .

HY-14925

Lapaquistat 2 Publications Verification T-91485	Endogenous Metabolite Drug Metabolite	Metabolic Disease
Lapaquistat (T-91485), a **cholesterol biosynthesis** inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-116572A

TASIN-1	Reactive Oxygen Species (ROS) JNK Apoptosis Caspase	Cancer
TASIN-1 is a selective inhibitor of truncated *APC ^TR* (adenomatous polyposis coli gene) that exerts cytotoxic effects by inhibiting cholesterol biosynthesis. TASIN-1 specifically targets colorectal cancer (CRC) cells carrying APC truncated mutations, while having no significant toxicity to wild-type APC cells. TASIN-1 exerts cytotoxic effects by targeting Emopamil binding protein (EBP) to inhibit cholesterol biosynthesis, triggering endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) generation, and JNK-mediated apoptosis, and inhibiting Akt survival signaling. TASIN-1 can be used to prevent and intervene in APC mutant colorectal cancer .

HY-10016

E 2012 5+ Cited Publications	γ-secretase	Neurological Disease
E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .

HY-104051

Monacolin J Antibiotic MB 530A; Lovastatin diol lactone	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease
Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase.

HY-115625

AG-205	Progesterone Receptor Apoptosis Glycosyltransferase	Cancer
AG-205 is a progesterone receptor membrane component 1 (PGRMC1) antagonist and CGT inhibitor, with an IC₅₀ of 50 μM against rat CGT. AG-205 exhibits antimitotic, antimigratory and anti-invasive activities. AG-205 increases the expression of genes encoding cholesterol biosynthesis pathway or steroidogenic enzymes. AG-205 promotes the regulation of cell cycle by apoptosis and reduces the migratory and invasive capacities of ovarian and breast cancer cells. AG-205 can be used in research related to renal cancer and breast cancer .

HY-N10549

Gigantol 1 Publications Verification	Ferroptosis c-Myc Glutathione Peroxidase JNK Reactive Oxygen Species (ROS) GSK-3	Infection Metabolic Disease Cancer
Gigantol is an orally active bibenzyl compound. Gigantol targets MYC to promote its ubiquitin-proteasomal degradation and inhibit the growth of lung cancer cells. Gigantol exerts anti-lung cancer activity by inducing ferroptosis (Ferroptosis) via the SLC7A11-GPX4 axis. Gigantol restores the sensitivity of mcr-harboring multidrug-resistant bacteria to colistin. Gigantol ameliorates carbon tetrachloride-induced liver injury by inhibiting the activation of the JNK/cPLA2/12-LOX inflammatory pathway. Gigantol promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells. Gigantol can be used in studies related to diseases such as lung cancer, multidrug-resistant Gram-negative bacterial infections, and acute liver injury .

HY-43515

ESI1	Endogenous Metabolite	Metabolic Disease
ESI1 is a small molecule epigenetic silencing inhibitor. ESI1 can trigger the formation of nuclear condensates of key lipid metabolism regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. ESI1 can promote myelin regeneration in demyelinated animal models and facilitate de novo myelination on regenerating CNS axons, reversing age-related declines in cognitive abilities .

HY-139576B

Larsucosterol trimethylamine DUR-928 trimethylamine	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-176557

NCI677397	Deubiquitinase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Autophagy	Cancer
NCI677397 is a USP24 inhibitor. NCI677397 increases lipid ROS, activates cholesterol and fatty acid biosynthesis, degrades ABC transporters, GPX4 and DHFR through the autophagy pathway, decreases the level of P-gp and ultimately leads to ferroptosis in drug-resistant cancer cells. NCI677397 can be used for the study of lung caner and brain cancer .

HY-Y0889A

1-(2,3-Dichlorphenyl)piperazine hydrochloride	Endogenous Metabolite	Metabolic Disease
1-(2,3-Dichlorphenyl)piperazine hydrochloride is a potent DHCR7 inhibitor with the activity of inhibiting cholesterol biosynthesis. 1-(2,3-Dichlorphenyl)piperazine hydrochloride is often used in biological research to evaluate the function of cholesterol biosynthesis pathway. The application of 1-(2,3-Dichlorphenyl)piperazine hydrochloride is of great significance for understanding diseases related to cholesterol biosynthesis .

HY-122410

Dihydrolanosterol 1 Publications Verification	Cytochrome P450	Others
Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor. .

HY-Y0889

1-(2,3-Dichlorphenyl)piperazine	Endogenous Metabolite	Metabolic Disease
1-(2,3-Dichlorphenyl)piperazine is a potent DHCR7 inhibitor with the activity of inhibiting cholesterol biosynthesis. 1-(2,3-Dichlorphenyl)piperazine is often used in biological research to evaluate the function of cholesterol biosynthesis pathway. The application of 1-(2,3-Dichlorphenyl)piperazine is of great significance for understanding diseases related to cholesterol biosynthesis .

HY-139576

Larsucosterol DUR-928	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-B2097

Incadronate disodium YM 175; Bisphonal	Farnesyl Transferase	Metabolic Disease
Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (K_i=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC₅₀=64 μM). Incadronate disodium has the potential for malignant tumors research .

HY-B1189S

Meglutol-d3 Dicrotalic acid-d₃; 3-Hydroxy-3-methylglutaric acid-d₃	Autophagy HMG-CoA Reductase (HMGCR) Endogenous Metabolite	Cardiovascular Disease
Meglutol-d₃ is the deuterium labeled Meglutol . Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-139576C

Larsucosterol ammonium DUR-928 ammonium	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) ammonium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol ammonium as a potent endogenous regulator decreases lipogenesis. Larsucosterol ammonium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-116572

TASIN-1 hydrochloride	Reactive Oxygen Species (ROS) JNK Apoptosis Caspase	Cancer
TASIN-1 hydrochloride is a selective inhibitor of truncated *APC ^TR* (adenomatous polyposis coli gene) that exerts cytotoxic effects by inhibiting cholesterol biosynthesis. TASIN-1 hydrochloride specifically targets colorectal cancer (CRC) cells carrying APC truncated mutations, while having no significant toxicity to wild-type APC cells. TASIN-1 hydrochloride exerts cytotoxic effects by targeting Emopamil binding protein (EBP) to inhibit cholesterol biosynthesis, triggering endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) generation, and JNK-mediated apoptosis, and inhibiting Akt survival signaling. TASIN-1 hydrochloride can be used to prevent and intervene in APC mutant colorectal cancer .

HY-113224R

Desmosterol (Standard)	Reference Standards Endogenous Metabolite LXR Fatty Acid Synthase (FASN) Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Desmosterol (Standard) is the analytical standard of Desmosterol. This product is intended for research and analytical applications. Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism [1]. Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases [1][2][3].

HY-N12846

Neokadsuranic acid A	Others	Metabolic Disease
Neokadsuranic acid A is a cholesterol biosynthesis inhibitor that reduces the activity of cholesterol. Neokadsuranic acid A is a triterpenoid compound that can be isolated from Kadsura heteroclita, a plant of the Schisandraceae family. Neokadsuranic acid A can be used to study the cholesterol biosynthesis pathway and its role in traditional medicine .

HY-N10232

Agistatin E	Others	Infection
Agistatin E is a pyranacetal originally isolated from a Fusarium sp. that inhibits the **cholesterol biosynthesis** .

HY-N10231

Agistatin D	Others	Infection Inflammation/Immunology
Agistatin D is a pyranacetal originally isolated from a Fusarium sp. that inhibits the **cholesterol biosynthesis** .

HY-125666

Agistatin B	Fungal	Infection
Agistatin B, isolated from fungus, is a mycotoxin. Agistatin B inhibits **cholesterol synthesis** .

HY-157528

CJ28	Endogenous Metabolite	Cancer
CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .

HY-W753726

Dihydromonacolin L	Drug Intermediate	Metabolic Disease
Dihydromonacolin L, a potent inhibitor of cholesterol biosynthesis, can be isolated from cultures of a mutant of Monascus niber .

HY-169040

28-Aminobetulin	Fatty Acid Synthase (FASN)	Metabolic Disease
28-Aminobetulin is a pentacyclic triterpenoid and a derivative of the cholesterol biosynthesis inhibitor Betulin (HY-N0083).

HY-122410S

Dihydrolanosterol-d7	Isotope-Labeled Compounds Cytochrome P450	Others
Dihydrolanosterol-d₇ is deuterium labeled Dihydrolanosterol. Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor .

HY-108040

NCX-6560	NO Synthase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
NCX-6560 is an orally active nitric oxide releasing derivative of atorvastatin that inhibits cholesterol biosynthesis and has anti-inflammatory and antithrombotic activity .

HY-139576A

Larsucosterol sodium DUR-928 sodium	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-100299A

RPR107393	Farnesyl Transferase	Cardiovascular Disease Metabolic Disease
RPR107393 is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 inhibits rat liver microsomal squalene synthase with an IC₅₀ value of 0.8 nM. RPR107393 reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 reduces plasma cholesterol in rats and marmosets. RPR107393 can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis .

HY-158050

PXB17	c-Fms	Cancer
PXB17 can inhibit CSF1R (IC₅₀ = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .

HY-100299

RPR107393 free base	Farnesyl Transferase	Cardiovascular Disease Metabolic Disease
RPR107393 free base is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 free base inhibits rat liver microsomal squalene synthase with an IC₅₀ value of 0.8 nM. RPR107393 free base reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 free base reduces plasma cholesterol in rats and marmosets. RPR107393 free base can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis ^[1][2].

HY-B1189R

Meglutol (Standard) Dicrotalic acid (Standard); 3-Hydroxy-3-methylglutaric acid (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Reference Standards	Cardiovascular Disease Metabolic Disease
Meglutol (Standard) is the analytical standard of Meglutol. This product is intended for research and analytical applications. Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-113725

L 668411	HMG-CoA Reductase (HMGCR)	Others
L 668411 is a β-lactone inhibitor with activity against 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis. L 668411 inhibits rat liver cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase and [14C] acetate incorporation into sterols in cultured Hep G2 cells, and the inhibition appears to be irreversible in cells but reversible in cultured cells and animals.

HY-W988083

Decarestrictin B	Endogenous Metabolite	Metabolic Disease
Decarestrictin B is a decanolactone that can be isolated from penicillium strains. Decarestrictin B is an inhibitor of **cholesterol biosynthesis** .

HY-N14783

Decarestrictin M	Endogenous Metabolite	Metabolic Disease
Decarestrictin M is a decanolactone that can be isolated from penicillium strains. Decarestrictin M is an inhibitor of **cholesterol biosynthesis** .

HY-139090

3-Oxobetulin acetate 28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin	Bacterial HIV Drug Derivative	Cancer
3-Oxobetulin acetate (28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin) is a derivative of betulin (HY-N0083), a cholesterol biosynthesis inhibitor. 3-Oxobetulin acetate inhibits the growth of P388 murine lymphocytic leukemia cells (EC50=0.12 μg/mL) and human MCF-7 breast cancer, SF-268 CNS cancer, H460 lung cancer, and KM20L2 colon cancer cells (GI50s=8, 10.6, 5.2, and 12.7 μg/mL), but not BxPC-3 pancreatic cancer cells or DU145 prostate cancer cells (GI50s=>10 μg/mL for both). 3-Oxobetulin acetate inhibits the replication of X4-tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC50=13.4 μM). 3-Oxobetulin acetate is also effective against Listeria donovani amastigotes.

HY-179686

CYP11A1-IN-2	Cytochrome P450	Cancer
CYP11A1-IN-2 (Compound 61) is a selective cholesterol side-chain cleavage enzyme (CYP11A1) inhibitor. CYP11A1-IN-2 can inhibitor steroid biosynthesis and can be used for the research of steroid hormone-dependent cancers, such as prostate cancer .

HY-107420S

AY 9944-d8	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
AY 9944-d₈ is the deuterium labeled AY 9944 (HY-107420). AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC₅₀ of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol.

HY-107420R

AY 9944 (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease
AY 9944 (Standard) is the analytical standard of AY 9944 (HY-107420). This product is intended for research and analytical applications. AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC₅₀ of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol .

HY-10016R

E 2012 (Standard)	γ-secretase Reference Standards	Neurological Disease
E 2012 (Standard) is the analytical standard of E 2012 (HY-10016). This product is intended for research and analytical applications. E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .

製品番号	製品名	Category	Target	構造式